

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041802 A1

(51) International Patent Classification⁷: **C07D 295/155**,
333/20, 307/52, 213/36, 277/28, A61K 31/495, 31/496,
A61P 25/04

(21) International Application Number:
PCT/SE2003/001707

(22) International Filing Date:
5 November 2003 (05.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203303-3 7 November 2002 (07.11.2002) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, William** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **GRIFFIN, Andrew** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **JONES, Paul** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA). **PAGÉ, Daniel** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S

1Z9 (CA). **PLOBECK, Niklas** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Québec H4S 1Z9 (CA).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS



(I)

(57) Abstract: Compounds of general formula (I) wherein R₁, R₂ and R₃ are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

WO 2004/041802 A1

4(PHENYL-PIPERAZINYLMETHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain, anxiety and functional gastrointestinal disorders.

10

2. Discussion of Relevant Art

The receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the δ receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the δ receptor have also been shown to possess immunomodulatory activities.

15

The identification of at least three different populations of opioid receptors (μ , δ and κ) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.

20

With few exceptions, currently available selective opioid δ ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic δ -agonist is SNC80 (Bilsky E.J. et al., Journal of Pharmacology and Experimental Therapeutics, 273(1), pp. 359-366 (1995)).

25

Many δ agonist compounds that have been identified in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that many of these δ agonist compounds show significant convulsive effects when administered systemically.

30

U.S. Patent No. 6,130,222 to Roberts et al. describes some δ -agonists.

However, there is still a need for improved δ -agonists.

DESCRIPTION OF THE INVENTION**Definitions**

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979, which is incorporated by references herein for its exemplary chemical structure names and rules on naming chemical structures.

The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

The term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. An "alkyl" may optionally contain one or more unsaturated carbon-carbon bonds.

The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.

The term "alkenyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.

The term "alkynyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.

The term "cycloalkyl," used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.

The term "cycloalkenyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.

5 The term "cycloalkynyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

The term "aryl" used alone or as suffix or prefix, refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 10 14 carbon atoms.

The term "arylene" used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to link two structures together.

15 The term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may 20 contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may not have aromatic character.

The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, 25 independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

30 The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

The term "heterocyclyl" used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.

The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom,
5 which serves to links two structures together.

The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.

The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character.

10 The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.

The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.

The term "six-membered" used as prefix refers to a group having a ring that
15 contains six ring atoms.

The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

20 Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.

A six-membered ring heteroaryl is a heteroaryl with a ring having six ring
25 atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more
30 C₁₋₆hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃,

-C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a C₁₋₆hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc.,
5 wherein the nitro, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.

The term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first
10 structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-
15 dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihdropyran, tetrahydropyran, 1,4-dihdropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

20 In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.

25 Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine,
30 naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole,

benztriazole, thioxanthine, carbazole, carboline, acridine, pyrrolizidine, and quinolizidine.

In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings
5 includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

Heterocyclyl includes, for example, monocyclic heterocyclyls, such as:
aziridinyl, oxiranyl, thiiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl,
10 imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-
15 dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-
20 thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-
25 benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indoliziny, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl,
30 phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl.

In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula $-O-R$, wherein R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.

The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula $-NRR'$, wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.


Halogen includes fluorine, chlorine, bromine and iodine.

"Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.

"RT" or "rt" means room temperature.

Description of Embodiments

In one aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers thereof, enantiomers thereof, and mixtures thereof:



wherein

R^1 is selected from $-H$, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups selected from $-R$, $-NO_2$, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$,
 5 $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl;

R^2 is selected from $-H$, C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl; and

R^3 is selected from C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl.

In another embodiment, the compounds of the present invention are those of formula I, wherein

20 R^1 is $-CH_2-R^4$, wherein R^4 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

25 R^2 is selected from $-H$ and C_{1-3} alkyl; and

R^3 is selected from C_{1-6} alkyl, and C_{3-6} cycloalkyl.

In another embodiment, the compounds of the present invention are those of formula I, wherein R^1 is $-CH_2-R^4$, wherein R^4 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl and thiazolyl;

R^2 is selected from $-H$ and methyl; and

R^3 is selected from methyl, ethyl, propyl and isopropyl.

In a further embodiment, the compounds of the present invention are those of formula I, wherein R¹ is -H;

R² is selected from -H and C₁₋₃alkyl; and

R³ is selected from C₁₋₆alkyl, and C₃₋₆cycloalkyl.

5

It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic

organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt
5 such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain
10 etc. This list should however not be interpreted as exhaustive.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

15 Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

20 Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation,
25 functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

30 Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain

the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: chronic pain, neuropathic pain, acute pain, back pain, cancer pain, and visceral pain.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

In one embodiment of the invention, the route of administration may be orally, intravenously or intramuscularly.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.

Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For example, sterile water or water propylene glycol solutions of the active compounds

may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

5 Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical
10 formulation art.

Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total composition.

15 A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

20 Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of formula I for the manufacture of a medicament for the therapy of pain.

25 Additionally provided is the use of any compound according to Formula I for the manufacture of a medicament for the therapy of various pain conditions including, but not limited to: chronic pain, neuropathic pain, acute pain, back pain, cancer pain, and visceral pain.

30 A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such therapy.


Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

5 Particularly, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.

Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association
10 with a pharmaceutically acceptable carrier use in any of the conditions discussed above.


In a further aspect, the present invention provides a method of preparing a compound of formula I.

In one embodiment, the invention provides a process for preparing a
15 compound of formula II, comprising:




II

a) reacting a compound of formula III:




III

20 with a compound of formula IV



in the presence of benzotriazole; and

- b) reacting a product formed in step a) with a compound of formula V to form
 5 the compound of formula II,




wherein

- 10 R^8 is selected from C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;
- 15 M is selected from Li, Na, K, $-ZnX^1$, and $-MgX^1$, wherein X^1 is a halogen; and R^9 is selected from hydrogen, -R, $-NO_2$, -OR, -Cl, -Br, -I, -F, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, -SH, -NHR, $-NR_2$, -SR, $-SO_3H$, $-SO_2R$, $-S(=O)R$, -CN, -OH, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} hydrocarbyl.

20


In another embodiment, the invention provides a process for preparing a compound of formula VII:

16

VII,

comprising:

reacting a compound of formula VIII

VIIIwith a C₁₋₆alkylcarbamate to form the compound of formula VII,

wherein

R⁸ is selected from C₁₋₆alkyl-O-C(=O)-, C₆₋₁₀aryl-C₁₋₄alkyl, and


10 C₂₋₆heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆alkyl-O-C(=O)-, C₆₋₁₀aryl-C₁₋₄alkyl, and C₂₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl;

15 X is selected from halogen, triflate, and sulfonamide; and

R¹¹ is a C₁₋₆alkyl.


In a further embodiment, the invention provides a process for preparing a compound of formula X,

17

X

comprising:

reacting a compound of formula IX,

IXwith R⁴-CHO to form the compound of formula X,

wherein

R⁴ is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from C₁₋₆alkyl, halogenated C₁₋₆alkyl, -NO₂, -CF₃, C₁₋₆ alkoxy, chloro, fluoro, bromo, and iodo;


R² is selected from -H, C₁₋₆alkyl and C₃₋₆cycloalkyl, wherein said C₁₋₆alkyl and C₃₋₆cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl; and

18

- R^3 is selected from C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR,
- 5 wherein R is, independently, a hydrogen or C_{1-6} alkyl.

Particularly, the compounds of the present invention can be prepared according to the synthetic routes as exemplified in Schemes 1-7.


Scheme 1




10

19

Scheme 2




Scheme 3




20

Scheme 4




21

Scheme 5




Scheme 6




23

Scheme 7



Accordingly, a further aspect of the invention is a compound of formula XI, a
 5 pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures
 thereof:

24

XI

wherein

- R¹ is selected from -H, C₆₋₁₀aryl, C₂₋₆heteroaryl, C₆₋₁₀aryl-C₁₋₄alkyl, and C₂₋₆heteroaryl-C₁₋₄alkyl, wherein said C₆₋₁₀aryl, C₂₋₆heteroaryl, C₆₋₁₀aryl-C₁₋₄alkyl, and C₂₋₆heteroaryl-C₁₋₄alkyl are optionally substituted with one or more groups selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl.

BIOLOGICAL EVALUATION

- The compounds of the invention are found to be active towards δ receptors in warm-blooded animal, e.g., human. Particularly the compounds of the invention are found to be effective δ receptor ligands. *In vitro* assays, *infra*, demonstrate these surprising activities, especially with regard to agonists potency and efficacy as demonstrated in the rat brain functional assay and/or the human δ receptor functional assay (low). This feature may be related to *in vivo* activity and may not be linearly correlated with binding affinity. In these *in vitro* assays, a compound is tested for their activity toward δ receptors and IC₅₀ is obtained to determine the selective activity for a particular compound towards δ receptors. In the current context, IC₅₀ generally refers to the concentration of the compound at which 50% displacement of a standard radioactive δ receptor ligand has been observed.

- The activities of the compound towards κ and μ receptors are also measured in a similar assay.

In vitro modelCell culture

- 5 A. Human 293S cells expressing cloned human κ , δ and μ receptors and neomycin resistance are grown in suspension at 37°C and 5% CO₂ in shaker flasks containing calcium-free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 µg/ml geneticin.
- 10 B. Rat brains are weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains are homogenized with a polytron for 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride added just prior use to 0.5MmM from a 0.5M stock in DMSO:ethanol).

Membrane preparation

- 15 Cells are pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec. The suspension is spun at 1000g (max) for 10 min at 4°C. The supernatant is saved on ice and the pellets resuspended and spun as before. The supernatants from both spins
- 20 are combined and spun at 46,000 g(max) for 30 min. The pellets are resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again. The final pellets are resuspended in membrane buffer (50 mM Tris, 0.32 M sucrose, pH 7.0). Aliquots (1 ml) in polypropylene tubes are frozen in dry ice/ethanol and stored at -70°C until use. The protein concentrations are determined by a modified Lowry assay with sodium
- 25 dodecyl sulfate.

Binding assays

- 30 Membranes are thawed at 37°C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCl₂, 1 mg/ml BSA (Sigma A-7888), pH 7.4, which is stored at 4°C after filtration through a 0.22 µm filter, and to which has been freshly added 5 µg/ml aprotinin, 10 µM bestatin, 10 µM diprotin A, no DTT). Aliquots of 100 µl are added to iced 12x75 mm polypropylene

tubes containing 100 μ l of the appropriate radioligand and 100 μ l of test compound at various concentrations. Total (TB) and nonspecific (NS) binding are determined in the absence and presence of 10 μ M naloxone respectively. The tubes are vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly
5 vacuum-filtered and washed with about 12 ml/tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM $MgCl_2$) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyleneimine. The radioactivity (dpm) retained on the filters is measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid. If the assay is set up in 96-place deep well plates, the filtration is
10 over 96-place PEI-soaked unifilters, which are washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h. The filter plates are counted in a TopCount (Packard) after adding 50 μ l MS-20 scintillation fluid/well.

Functional Assays

15 The agonist activity of the compounds is measured by determining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled. In the GTP binding assay, GTP[γ]³⁵S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate
20 GTP[γ]³⁵S binding in these membranes. The EC_{50} and E_{max} values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltrindole are performed to verify that agonist activity is mediated through delta receptors. For human δ receptor functional assays, EC_{50} (low) is
25 measured when the human δ receptors used in the assay were expressed at lower levels in comparison with those used in determining EC_{50} (high). The E_{max} values were determined in relation to the standard δ agonist SNC80, i.e., higher than 100% is a compound that have better efficacy than SNC80.

Procedure for rat brain GTP

30 Rat brain membranes are thawed at 37°C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP γ S binding (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM $MgCl_2$, pH 7.4, Add fresh: 1 mM DTT, 0.1%

- BSA). 120 μ M GDP final is added membranes dilutions. The EC₅₀ and E_{max} of compounds are evaluated from 10-point dose-response curves done in 300 μ l with the appropriate amount of membrane protein (20 μ g/well) and 100000-130000 dpm of GTP γ ³⁵S per well (0.11 -0.14nM). The basal and maximal stimulated binding are
- 5 determined in absence and presence of 3 μ M SNC-80

Data analysis

- The specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB.
- 10 Values of IC₅₀ and Hill coefficient (n_H) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GraphPad Prism, SigmaPlot, or ReceptorFit. Values of K_i were calculated from the Cheng-Prussoff equation. Mean \pm S.E.M. values of IC₅₀, K_i and n_H were reported for ligands tested in at least three displacement curves.
- 15 Based on the above testing protocols, we find that the compounds of the present invention and some of the intermediates used in the preparation thereof are active toward human δ receptors. Biological activity of the compounds and selected intermediates of the present invention is indicated in Tables 1 and 2.

20 Table 1

Compd. #	Human δ (nM)			Human κ	Human μ	RAT BRAIN (nM)	
	IC ₅₀	EC ₅₀ (high)	%E _{Max} (high)	IC ₅₀	IC ₅₀	EC ₅₀	%E _{Max}
1-11	0.25- 0.74	0.55-1.93	89-102	247-1636	93-1100	0.93-16.7	135-170

Table 2

Compd. #	Human δ (nM)			Human κ	Human μ
	IC ₅₀	EC ₅₀ (low)	%E _{Max} (low)	IC ₅₀	IC ₅₀
12-23,					

and Interm. 4a	0.18-4.18	3.26-484	58-106	1277-8728	92-6560
----------------------	-----------	----------	--------	-----------	---------

Receptor Saturation Experiments

Radioligand K_d values are determined by performing the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated K_d (up to 10 times if amounts of radioligand required are feasible). The specific radioligand binding is expressed as pmole/mg membrane protein. Values of K_d and B_{max} from individual experiments are obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one-site model.

DETERMINATION OF MECHANO-ALLODYNIA USING VON FREY TESTING

Testing is performed between 08:00 and 16:00h using the method described by Chaplan et al. (1994). Rats are placed in Plexiglas cages on top of a wire mesh bottom which allows access to the paw, and are left to habituate for 10-15 min. The area tested is the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw is touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, Ill, USA). The von Frey hair is applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, and held for approximately 6-8 seconds. A positive response is noted if the paw is sharply withdrawn. Flinching immediately upon removal of the hair is also considered a positive response. Ambulation is considered an ambiguous response, and in such cases the stimulus is repeated.

TESTING PROTOCOL

The animals are tested on postoperative day 1 for the FCA-treated group. The 50% withdrawal threshold is determined using the up-down method of Dixon (1980).

Testing is started with the 2.04 g hair, in the middle of the series. Stimuli are always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus is presented; in the event of paw withdrawal, the next weaker stimulus is chosen.

- 5 Optimal threshold calculation by this method requires 6 responses in the immediate vicinity of the 50% threshold, and counting of these 6 responses begins when the first change in response occurs, e.g. the threshold is first crossed. In cases where thresholds fall outside the range of stimuli, values of 15.14 (normal sensitivity) or 0.41 (maximally allodynic) are respectively assigned. The resulting pattern of positive and negative responses is tabulated using the convention, X = no withdrawal; O = withdrawal, and the 50% withdrawal threshold is interpolated using the formula:

$$50\% \text{ g threshold} = 10^{(X_f + k\delta)} / 10,000$$

- 15 where X_f = value of the last von Frey hair used (log units); k = tabular value (from Chaplan et al. (1994)) for the pattern of positive / negative responses; and δ = mean difference between stimuli (log units). Here $\delta = 0.224$.

Von Frey thresholds are converted to percent of maximum possible effect (% MPE), according to Chaplan et al. 1994. The following equation is used to compute
20 % MPE:

$$\% \text{ MPE} = \frac{\text{Drug treated threshold (g)} - \text{allodynia threshold (g)}}{\text{Control threshold (g)} - \text{allodynia threshold (g)}} \times 100$$

25 ADMINISTRATION OF TEST SUBSTANCE

Rats are injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varies depending upon the nature of the test compound.

30

Writhing Test

Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.

5 A complete and typical Writhing reflex is considered only when the following elements are present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of *both* paws is observable. In this assay, compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1-100 $\mu\text{mol/kg}$.

10

(i) Solutions preparation

Acetic acid (AcOH): 120 μL of Acetic Acid is added to 19.88 ml of distilled water in order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.

15

Compound (drug): Each compound is prepared and dissolved in the most suitable vehicle according to standard procedures.

(ii) Solutions administration

20 The compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing. When the compound is delivered centrally: Intraventricularly (i.c.v.) or intrathecally (i.t.) a volume of 5 μL is administered.

25 The AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the average mice body weight) immediately prior to testing.

(iii) Testing

30 The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box" cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

For the anxiety and anxiety-like indications, efficacy has been established in the geller-seifter conflict test in the rat.

For the functional gastrointestinal disorder indication, efficacy can be established in the assay described by Coutinho SV *et al*, in American Journal of
5 Physiology - Gastrointestinal & Liver Physiology. 282(2):G307-16, 2002 Feb, in the rat.

ADDITIONAL IN VIVO TESTING PROTOCOLS

Subjects and housing

10 Naïve male Sprague Dawley rats (175-200g) are housed in groups of 5 in a temperature controlled room (22°C, 40-70% humidity, 12-h light/dark). Experiments are performed during the light phase of the cycle. Animals have food and water ad libitum and are sacrificed immediately after data acquisition.

15 Sample

Compound (Drug) testing includes groups of rats that do not receive any treatment and others that are treated with E. coli lipopolysaccharide(LPS). For the LPS-treated experiment, four groups are injected with LPS, one of the four groups is then vehicle-treated whilst the other three groups are injected with the drug and its
20 vehicle. A second set of experiments are conducted involving five groups of rats; all of which receive no LPS treatment. The naïve group receives no compound (drug) or vehicle; the other four groups are treated with vehicle with or without drug. These are performed to determine anxiolytic or sedative effects of drugs which can contribute to a reduction in USV.

25

Administration of LPS

Rats are allowed to habituate in the experimental laboratory for 15-20 min prior to treatment. Inflammation is induced by administration of LPS (endotoxin of gram-negative E. coli bacteria serotype 0111:B4, Sigma). LPS (2.4µg) is injected
30 intracerebro-ventricularly (i.c.v.), in a volume of 10µl, using standard stereotaxic surgical techniques under isoflurane anaesthesia. The skin between the ears is pushed rostrally and a longitudinal incision of about 1cm is made to expose the skull surface.

The puncture site is determined by the coordinates: 0.8 mm posterior to the bregma, 1.5 mm lateral (left) to the lambda (sagittal suture), and 5 mm below the surface of the skull (vertical) in the lateral ventricle. LPS is injected via a sterile stainless steel needle (26-G 3/8) of 5 mm long attached to a 100- μ l Hamilton syringe by
5 polyethylene tubing (PE20; 10-15 cm). A 4 mm stopper made from a cut needle (20-G) is placed over and secured to the 26-G needle by silicone glue to create the desired 5mm depth.

Following the injection of LPS, the needle remains in place for an additional 10 s to allow diffusion of the compound, then is removed. The incision is closed, and
10 the rat is returned to its original cage and allowed to rest for a minimum of 3.5h prior to testing.

Experimental setup for air-puff stimulation

The rats remains in the experimental laboratory following LPS injection and
15 compound (drug) administration. At the time of testing all rats are removed and placed outside the laboratory. One rat at a time is brought into the testing laboratory and placed in a clear box ($9 \times 9 \times 18$ cm) which is then placed in a sound-attenuating ventilated cubicle measuring 62(w) \times 35(d) \times 46(h) cm (BRS/LVE, Div. Tech-Serv Inc). The delivery of air-puffs, through an air output nozzle of 0.32 cm, is controlled.
20 by a system (AirStim, San Diego Instruments) capable of delivering puffs of air of fixed duration (0.2 s) and fixed intensity with a frequency of 1 puff per 10s. A maximum of 10 puffs are administered, or until vocalisation starts, whichever comes first. The first air puff marks the start of recording.

25 Experimental setup for and ultrasound recording

The vocalisations are recorded for 10 minutes using microphones (G.R.A.S. sound and vibrations, Vedbaek, Denmark) placed inside each cubicle and controlled by LMS (LMS CADA-X 3.5B, Data Acquisition Monitor, Troy, Michigan) software. The frequencies between 0 and 32000Hz are recorded, saved and analysed by the
30 same software (LMS CADA-X 3.5B, Time Data Processing Monitor and UPA (User Programming and Analysis)).

Compounds (Drugs)

All compounds (drugs) are pH-adjusted between 6.5 and 7.5 and administered at a volume of 4 ml/kg. Following compound (drug) administration, animals are returned to their original cages until time of testing.

5

Analysis

The recording is run through a series of statistical and Fourier analyses to filter (between 20-24kHz) and to calculate the parameters of interest. The data are expressed as the mean \pm SEM. Statistical significance is assessed using T-test for comparison between naive and LPS-treated rats, and one way ANOVA followed by Dunnett's multiple comparison test (post-hoc) for drug effectiveness. A difference between groups is considered significant with a minimum p value of ≤ 0.05 . Experiments are repeated a minimum of two times.

15 EXAMPLES

The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.

20

INTERMEDIATE 1: *N,N*-Diethyl-4-formylbenzamide

To a suspension of 4-carboxybenzaldehyde (30g, 0.2 mole) in 100 ml of toluene was added SOCl_2 (97 ml, 1.3 moles) at 60 °C. The reaction was heated until gas evolution ceased followed by evaporation to dryness with toluene (3 x 50 mL). This yielded a residue, which was dissolved in CH_2Cl_2 (200 mL). To this solution, cooled in an ice bath while stirring, was added diethylamine (50 mL). Stirring was continued for one hour and then the mixture heated at reflux for a further hour. After cooling, the mixture was washed successively with H_2O , 2 N HCl, H_2O then 2 N NaOH and finally with H_2O . The solution was dried over MgSO_4 , filtered and concentrated to dryness yielding 41 g of oil. Distillation at 140-150 °C/1.5 torr gave 36.9 g, 90 % of **INTERMEDIATE 1**.

30

**INTERMEDIATE 2: *tert*-Butyl 4-((3-bromophenyl){4-
[(diethylamino)carbonyl]phenyl)methyl} piperazine-1-carboxylate**

A solution of **INTERMEDIATE 1** (6.84 g, 33.3 mmol) benzotriazole (3.96 g, 33.3 mmol) and N-Boc piperidine (6.19 g, 33.3 mmol) in 200 mL of toluene was
5 heated over night under Dean-Stark conditions. The reaction was concentrated, dissolved in 45 ml of dry THF and cooled in an ice bath. To this was canulated 3-bromophenylzinc iodide (0.5 M in THF, 100 mL, 50 mmol) over 15 minutes. The reaction was warmed to room temperature stirred for 30 minutes then heated overnight at 50 °C. The reaction mixture was quenched with NH₄Cl, stirred for 15
10 minutes then extracted 4 times with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered and concentrated. The resulting oil was purified by flash chromatography eluting ethyl acetate/heptane 30/70 to 50/50. Yield: 5.86 g, 33 % of **INTERMEDIATE 2**.

**INTERMEDIATE 3: 4-[[4-[(diethylamino)carbonyl]phenyl][3-
[(methoxycarbonyl)amino]phenyl)methyl]-1-piperazinecarboxylic acid, 1,1-
dimethylethyl ester**

To a solution of **INTERMEDIATE 2** (5.39 g, 10.17 mmol) in dry dioxane, while bubbling N₂, was added methyl carbamate (0.99 g, 13.2 mmol), xantphos
20 (0.47g, 0.81 mmol), Cs₂CO₃ (4.63 g, 14.2 mmol) and Pd₂(dba)₃ (0.465 g, 0.51 mmol). The reaction was heated for 7 hrs at reflux, cooled and filtered through diatomaceous earth. The resulting oil was purified by flash chromatography 40/60 to 80/20 ethyl acetate/heptane. 3.3 g, 62 % of **INTERMEDIATE 3** was obtained.

**INTERMEDIATE 4: [3-[[4-[(diethylamino)carbonyl]phenyl]-1-
piperazinylmethyl]phenyl]- carbamic acid, methyl ester**

To a solution of **INTERMEDIATE 3** (0.788 g, 1.5 mmol) in 15 mL of CH₂Cl₂ at 0 °C was added TFA (1.15 ml, 15 mmol). This was stirred until completion by HPLC. The solution was concentrated, dissolved in 20 mL of ethyl acetate and
30 washed with 10 mL 2 N K₂CO₃. The organic layer was separated and the aqueous layer washed with 5 X 20 ml of ethyl acetate. The combined organic layers were dried over MgSO₄, filtered and concentrated yielding 570 mg, 89 % of

INTERMEDIATE 4. The **INTERMEDIATE 4** was separated by chiral HPLC on Chiralpak AD 20 % EtOH/80% Heptane yielding 200 mg of enantiomer **INTERMEDIATE 4a** and 185 mg of enantiomer **INTERMEDIATE 4b**.

5 Analytical Chiral HPLC Conditions:

Chiralpak AD 15 % EtOH/85% Heptane

Flow rate 1ml/minute

INTERMEDIATE 4a retention time 25.7minutes

INTERMEDIATE 4b retention time 17.5minutes

10

INTERMEDIATE 5: 4-Iodo-N,N-diethylbenzamide

To a mixture of 4-iodo-benzoyl chloride (75 g) in 500 mL CH₂Cl₂ was added a mixture of Et₃N (50 mL) and Et₂NH (100 mL) at 0 °C. After the addition, the resulting reaction mixture was warmed up to room temperature in 1 hr and was then washed with saturated ammonium chloride. The organic extract was dried (Na₂SO₄), filtered and concentrated. Residue was recrystallized from hot hexanes to give 80g of **INTERMEDIATE 5**.

15

INTERMEDIATE 6: 4-[hydroxy(3-nitrophenyl)methyl]-N,N-diethylbenzamide

20 **INTERMEDIATE 5**, *N,N*-Diethyl-4-iodobenzamide (5.0 g, 16 mmol), was dissolved in THF (150 mL) and cooled to -78 °C under nitrogen atmosphere. *n*-BuLi (15 mL, 1.07 M solution in hexane, 16 mmol) was added dropwise during 10 min at -65 to -78 °C. The solution was then cannulated into 3-nitrobenzaldehyde (2.4 g, 16 mmol) in toluene/THF (approx. 1:1, 100 mL) at -78 °C. NH₄Cl (aq.) was added after 30 min. After concentration *in vacuo*, extraction with EtOAc / water, drying (MgSO₄) and evaporation of the organic phase, the residue was purified by chromatography on silica (0 – 75% EtOAc/heptane) to give **INTERMEDIATE 6** (2.6 g, 50%). ¹H NMR (CDCl₃) δ 1.0-1.3 (m, 6H), 3.2, 3.5 (2m, 4H), 5.90 (s, 1H), 7.30-7.40 (m, 4H), 7.50 (m, 1H), 7.70 (d, J = 8 Hz, 1H), 8.12 (m, 1H), 8.28 (m, 1H).

25

30

INTERMEDIATE 7: Racemic *N,N*-diethyl-4-[(3-nitrophenyl)(1-piperazinyl)methyl]benzamide

To a solution of **INTERMEDIATE 6** (10.01g, 30.5 mmol) in dichloromethane (200 mL) was added thionyl bromide (2.58 mL, 33.6 mmol). After one hour at room temperature the reaction was washed with saturated aqueous sodium bicarbonate (100 mL) and the organic layer was separated. The aqueous layer was washed with dichloromethane (3 x 100 mL) and the combined organic extracts were dried (Na₂SO₄), filtered and concentrated.

The resulting product in the organic extracts was dissolved in acetonitrile (350 mL) and piperazine (10.5g, 122 mmol) was added. After heating the reaction for one hour at 65 °C the reaction was washed with saturated ammonium chloride/ethyl acetate and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were dried (Na₂SO₄), filtered and concentrated to give racemic **INTERMEDIATE 7**.

INTERMEDIATE 8: (-)-N,N-diethyl-4-[(3-nitrophenyl)(1-piperazinyl)methyl]benzamide

Racemic **INTERMEDIATE 7** is resolved to give enantiomerically pure **INTERMEDIATE 8** as follows:

INTERMEDIATE 7 was dissolved in ethanol (150 mL) and di-*p*-toluoyl-D-tartaric acid (11.79g, 1 equivalent) was added. The product precipitated out over a 12 hour period. The solid was collected by filtration and was redissolved in refluxing ethanol until all of the solid dissolved (approximately 1200 mL ethanol). Upon cooling the solid was collected by filtration and the recrystallation repeated a second time. The solid was collected by filtration and was treated with aqueous sodium hydroxide (2M) and was extracted with ethyl acetate. The organic extract was then dried (Na₂SO₄), filtered and concentrated to give 1.986g of enantiomerically pure **INTERMEDIATE 8**. ¹H NMR (CDCl₃) δ 1.11 (br s, 3H), 1.25 (br s, 3H), 2.37 (br s, 4H), 2.91 (t, J = 5 Hz, 4H), 3.23 (br s, 2H), 3.52 (br s, 2H), 4.38 (s, 1H), 7.31-7.33 (m, 2H), 7.41-7.43 (m, 2H), 7.47 (t, J = 8 Hz, 1H), 7.75-7.79 (m, 1H), 8.06-8.09 (m, 1H), 8.30-8.32 (m, 1H).

Chiral purity was determined by HPLC using the following conditions:

Chiralpack AD column (Daicel Chemical Industries)

Flow rate 1 ml/minute

Run time 30 minutes at 25 °C

Isocratic 15% ethanol 85% hexanes

Retention time of molecule = 20 minutes

- 5 **INTERMEDIATE 9** may be obtained by the above procedure but using di-*p*-toluoyl-L-tartaric acid in place of di-*p*-toluoyl-D-tartaric acid.

INTERMEDIATE 10: *N,N*-diethyl-4-[(3-nitrophenyl)[4-(phenylmethyl)-1-piperazinyl]methyl]-benzamide

- 10 To a solution of **INTERMEDIATE 8** (1.407g, 3.55 mmol) in 1,2-dichloroethane (30 mL) was added benzaldehyde (0.58 mL, 5.71 mmol) and sodium triacetoxyborohydride (1.21g, 5.71 mmol). After 20 hours at room temperature the reaction was quenched with aqueous sodium bicarbonate and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 x 50 mL) and
15 the combined organic extracts were dried (Na₂SO₄), filtered and concentrated. The residue was purified by flash chromatography, eluting 5% methanol in dichloromethane to give **INTERMEDIATE 10** as a colourless foam (1.576g, 91% yield).

20 **INTERMEDIATE 11: 4-[(3-aminophenyl)[4-(phenylmethyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide**

- To a solution of **INTERMEDIATE 10** (1.576g, 3.24 mmol) in a mixture of ethanol, tetrahydrofuran, water and aqueous saturated ammonium chloride (4:2:1:1 ratio v/v) (30 mL) was added granules of iron (1.80 g, 32.4 mmol). After 4 hours at
25 reflux (90 °C) the reaction was cooled to room temperature, filtered through celite and concentrated. To the residue was added aqueous sodium bicarbonate and dichloromethane. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3 x 50 mL) and the combined organic extracts were dried (Na₂SO₄), filtered and concentrated. The product was purified on silica gel
30 eluting with 1% to 5% methanol in dichloromethane to afford **INTERMEDIATE 11** (1.310g, 88% yield).

Chiral HPLC conditions:

Chiralpack AD column (Daicel Chemical Industries)

Flow rate: 1 ml/minute

Run time 30 minutes at 25 °C

Isocratic 30% isopropanol / 70% hexane

5 Retention time of molecule = 18.7 minutes

INTERMEDIATE 14: 4-[(S)-(3-aminophenyl)[4-(pyridin-3-ylmethyl)piperazin-1-yl]methyl]-N,N-diethylbenzamide

To a solution of **INTERMEDIATE 9** (452 mg) in 1,2-dichloroethane (10 ml)
10 was added 3-pyridine carboxaldehyde (215 µL; 2 eq) and sodium triacetoxyborohydride (483 mg; 2 eq). The reaction was stirred at room temperature under nitrogen for 18 hours and concentrated. Saturated sodium bicarbonate was added and the aqueous solution was extracted with three portions of dichloromethane and the combined organics were dried over anhydrous sodium sulfate, filtered and
15 concentrated to yield **INTERMEDIATE 12**. The crude **INTERMEDIATE 12** was dissolved in a mixture of ethanol, tetrahydrofuran, water and saturated ammonium chloride (4 ml; ratios 4:2:1:1 v/v). Iron nanoparticles (3 tips of spatula) were added and the solution was heated at 150°C for 10 minutes in the microwave. The resulting mixture was cooled, filtered through celite and concentrated. The residue was purified
20 by flash chromatography on silica gel, eluting with a gradient from 1% to 10% MeOH in dichloromethane to give **INTERMEDIATE 14** (312 mg, 60% yield) as a colourless solid.

INTERMEDIATE 15: 4-[(S)-(3-aminophenyl)[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]methyl]-N,N-diethylbenzamide

To a solution of **INTERMEDIATE 9** (479 mg) in 1,2-dichloroethane (13 ml)
was added 2-thiazole carboxaldehyde (212 µL; 2 eq) and sodium triacetoxyborohydride (510 mg; 2 eq). The reaction was stirred at room temperature under nitrogen for 18 hours. Saturated sodium bicarbonate was added and the aqueous
30 solution was extracted with three portions of dichloromethane and the combined organics were dried over anhydrous sodium sulfate, filtered and concentrated to give **INTERMEDIATE 13**. The crude **INTERMEDIATE 13** was dissolved in a mixture

of ethanol, tetrahydrofuran, water and saturated ammonium chloride (4 ml; ratios 4:2:1:1 v/v). Iron nanoparticles (3 tips of spatula) were added and the solution was heated at 150°C for 10 minutes in the microwave. The resulting mixture was cooled, filtered through celite and concentrated. The residue was purified by reverse phase
5 chromatography, eluting 10% to 45% acetonitrile in water containing 0.1% trifluoroacetic acid. The product was obtained as the trifluoroacetic acid salt and was lyophilized to give **INTERMEDIATE 15** (372 mg, 39% yield) as a colourless solid.


**INTERMEDIATE 16a or 16b: tert-Butyl 4-((3-aminophenyl){4-
10 [(diethylamino)carbonyl]phenyl)methyl}piperazine-1-carboxylate**

To a solution of **INTERMEDIATE 8 or 9** (300 mg) in dioxane (40 ml) was added di-tert-butyl dicarbonate (247 mg; 1.5 eq). Sodium carbonate (119 mg; 1.5 eq) was dissolved in water (15 ml) and then added in the dioxane solution. After 12 hours the solution was concentrated and saturated sodium bicarbonate was then added. The
15 aqueous solution was extracted with three portions of dichloromethane and the combined organics were dried over anhydrous sodium sulfate, filtered and concentrated to afford a white foam. Without further purification, the foam was then dissolved in a mixture of ethanol, tetrahydrofuran, water and saturated ammonium chloride (15 ml; ratios 4:2:1:1 v/v). Iron granules (422mg; 10 eq) were added and the
20 solution was heated at 90 °C for 1.5 hour. The resulting mixture was cooled, filtered through celite and concentrated. Saturated sodium bicarbonate was added and the aqueous solution was extracted with three portions of dichloromethane and the combined organics were dried over anhydrous sodium sulfate, filtered and concentrated to afford a white foam **INTERMEDIATE 16a or 16b**, respectively. The
25 product can be use without any further purification. (92-99 % yield). ¹H NMR (400MHz, CDCl₃) 1.06-1.16 (m, 3H), 1.17-1.26 (m, 3H), 1.44 (s, 9H), 2.28-2.39 (m, 4H), 3.20-3.31 (br s, 2H), 3.37-3.44 (br s, 2H), 3.48-3.58 (br s, 2H), 3.60-3.70 (br s, 2H), 4.12 (s, 1H), 6.51-6.55 (m, 1H), 6.72 (t, J = 2.13Hz, 1H), 6.79 (d, J = 8.17 Hz, 1H), 7.06 (t, J = 7.46Hz, 1H), 7.29 (d, J = 7.82Hz, 2H), 7.43 (d, J = 7.82Hz, 2H).

30

**COMPOUND 1: R-Methyl 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-
piperazin-1-yl)methyl]phenylcarbamate**

40



To a solution of **INTERMEDIATE 4a** (200 mg, 0.47 mmol) dissolved in 5 ml dichloroethane was added benzaldehyde (95.5 μ L, 0.94 mmol) and NaBH(OAc)₃ (200 mg, 0.94 mmol). The reaction was stirred at room temperature overnight. Then 5 ml of a saturated solution of NaHCO₃ was added and the aqueous layer extracted 4 times with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered and concentrated. Purification by reverse phase chromatography yielded 188 mg of **COMPOUND 1** under the conditions: LUNA C-18, gradient 10-50% B in 25 min, flow: 40mL/min, 20°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN. ¹H NMR (400 MHz, CD₃OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.31 (m, 2H), 3.04 (m, 2H), 3.24 (m, 4H), 3.39 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.34 (s, 2H), 4.43 (s, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, J = 8.2 Hz, 2 H), 7.48 (s, 5H), 7.55 (d, J = 8.2 Hz, 2 H), 7.70 (s, 1H). Anal. calcd for C₃₁H₃₈N₄O₃ x 2.10 C₂HF₃O₂ x 0.3 H₂O: C, 55.66; H, 5.40; N, 7.38. Found: C, 55.70; H, 5.24; N, 7.41. M.S (calcd): 515.30 (MH⁺), M.S (found): 515.55 (MH⁺). HPLC: k': 2.95; Purity: >99% (215nm), >99% (254nm), >99% (280nm). Conditions: Zorbax C-18, gradient 30-80% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >90% (215nm), >94% (254nm), >94% (280nm), Rt: 8.7 mins; Conditions: Chiralpak AD 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_D = -14.5^\circ$ (c = 0.74, EtOH).


COMPOUND 1: R-[3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-carbamic acid methyl ester (via another synthetic route)

Methyl chloroformate (0.008mL, 0.11 mmol) and zinc dust (8mg, 0.11 mmol) were stirred together in 1mL of dry toluene at room temperature under nitrogen for 10 minutes. A 1 mL toluene solution of **INTERMEDIATE 10** (50mg, 0.110mmol) was

then added dropwise and the reaction mixture was stirred at room temperature overnight. The solution was then diluted with dichloromethane and filtered. The organic phase was washed with saturated NaHCO₃ solution, brine and dried over anhydrous Na₂SO₄. The product was purified by silica gel flash chromatography
 5 eluting 50% hexanes in acetone to afford **COMPOUND 1** (28mg, 50% yield). ¹H NMR (400 MHz, CD₃OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.31 (m, 2H), 3.04 (m, 2H), 3.24 (m, 4H), 3.39 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.34 (s, 2H), 4.43 (s, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, J = 8.2 Hz, 2 H), 7.48 (s, 5H), 7.55 (d, J = 8.2 Hz, 2 H), 7.70 (s, 1H). Anal. calcd for C₃₁H₃₈N₄O₃ x 2.10 C₂HF₃O₂ x 0.3 H₂O: C, 55.66; H, 5.40; N, 7.38. Found: C, 55.70; H, 5.24; N, 7.41. M.S (calcd): 515.30 (MH⁺), M.S (found): 515.55 (MH⁺). HPLC: k': 2.95; Purity: >99% (215nm), >99% (254nm), >99% (280nm). Conditions: Zorbax C-18, gradient 30-80% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >90% (215nm) >94% (254nm) >94% (280nm), Retention time: 8.7 mins;
 10
 15 Conditions: Chiralpak AD 30 % IPA/70% hexane. Rotation: [α]_D¹⁷ = -14.5° (c = 0.74, EtOH).

COMPOUND 2: *S*- Methyl 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzylpiperazin-1-yl)methyl]phenylcarbamate

20




Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (185 mg, 0.43 mmol) and benzaldehyde (100 μL, 0.87 mmol) afforded 178 mg of

25 **COMPOUND 2**. ¹H NMR (400 MHz, CD₃OD): δ 1.09 (m, 3H), 1.22 (m, 3H), 2.31 (m, 2H), 3.04 (m, 2H), 3.24 (m, 4H), 3.40 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.34 (s,

2H), 4.43 (s, 1H), 7.09 (m, 1H), 7.19 (m, 2H), 7.32 (d, $J = 8.2$ Hz, 2 H), 7.48 (s, 5H), 7.55 (d, $J = 8.2$ Hz, 2 H), 7.71 (s, 1H). Anal. calcd for $C_{31}H_{38}N_4O_3 \times 1.60 C_2HF_3O_2 \times 0.6 H_2O$: C, 58.47; H, 5.77 N, 7.98. Found: C, 58.50; H, 5.70; N, 8.06. M.S (calcd): 515.30 (MH^+), M.S (found): 515.57 (MH^+). HPLC: k' : 3.00; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 30-80% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm) >99% (254nm) >99% (280nm), Rt: 11.2 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]_D^{17} = +17.1^\circ$ ($c = 0.77$, EtOH).

10

COMPOUND 3: *S*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate




15 Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 2-thiophenecarboxaldehyde (66 μ L, 0.70 mmol) afforded 213 mg of **COMPOUND 3**. 1H NMR (400 MHz, CD_3OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.35 (br s, 2H), 3.04 (br s, 2H), 3.32 (m, 6H), 3.51 (m, 2H), 3.72 (s, 3H), 4.44 (s, 1H), 4.58 (s, 2H), 7.09 (m, 1H), 7.13 (dd, $J = 3.7$, $J = 5.1$ Hz, 3H), 7.21 (m, 2 H), 7.32 (m, 3 H), 7.55 (d, $J = 8.2$ Hz, 2 H), 7.62 (m, 1 H), 7.69 (br s, 1H). Anal. calcd for $C_{29}H_{36}N_4O_3S \times 1.40 C_2HF_3O_2 \times 0.9 H_2O$: C, 54.84; H, 5.67; N, 8.04. Found: C, 54.76; H, 5.65; N, 8.09. M.S (calcd): 521.26 (MH^+), M.S (found): 521.26 (MH^+). HPLC: k' : 6.51; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 30-80% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >97% (215nm) >96%

20

25

(254nm) >96% (280nm), Rt: 22.2 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_D = +11.3^\circ$ (c = 1.14, MeOH).


COMPOUND 4: *R*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 2-thiophenecarboxaldehyde (66 μ L, 0.70 mmol) afforded 197 mg of **COMPOUND 4**. ^1H NMR (400 MHz, CD_3OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.35 (br s, 2H), 3.02 (br s, 2H), 3.32 (m, 6H), 3.51 (m, 2H), 3.72 (s, 3H), 4.44 (s, 1H), 4.58 (s, 2H), 7.09 (m, 1H), 7.13 (m, 1H), 7.21 (m, 2H), 7.32 (m, 3H), 7.55 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 5.1 Hz, 2H), 7.69 (s, 1H). Anal. calcd for $\text{C}_{29}\text{H}_{36}\text{N}_4\text{O}_3\text{S} \times 1.5 \text{ C}_2\text{HF}_3\text{O}_2 \times 0.9 \text{ H}_2\text{O}$: C, 55.13; H, 5.51; N, 8.04. Found: C, 55.14; H, 5.55; N, 8.11. M.S. (calcd): 521.26 (MH^+), M.S. (found): 521.23 (MH^+). HPLC: k': 6.59; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm) >99% (254nm) >99% (280nm), Retention time: 11.8 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_D = -12.8^\circ$ (c = 0.96, MeOH).


COMPOUND 5: *S*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-3-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate

44



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 3-thiophenecarboxaldehyde (66 μ L, 0.70 mmol) afforded 205 mg of **COMPOUND 5**. ^1H NMR (400 MHz, CD_3OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.36 (m, 2H), 2.99 (m, 2H), 3.28 (m, 6H), 3.51 (m, 2H), 3.72 (s, 3H), 4.36 (s, 2H), 4.42 (s, 1H), 7.09 (m, 1H), 7.21 (m, 3H), 7.32 (d, $J = 8.0$ Hz, 2 H), 7.55 (m, 3H), 7.67 (m, 2H). Anal. calcd for $\text{C}_{29}\text{H}_{36}\text{N}_4\text{O}_3\text{S} \times 1.7 \text{ C}_2\text{HF}_3\text{O}_2 \times 0.3 \text{ H}_2\text{O}$: C, 54.05; H, 5.36; N, 7.78. Found: C, 54.08; H, 5.36; N, 7.70. M.S. (calcd): 521.26 (MH^+), M.S. (found): 521.26 (MH^+). HPLC: k' : 6.68; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 13.3 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_{\text{D}} = +11.3^\circ$ ($c = 1.15$, MeOH).

COMPOUND 6: *R*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(thien-3-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate




20

Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 3-thiophenecarboxaldehyde (66 μ L, 0.70 mmol) afforded 199 mg of **COMPOUND 6**. ^1H NMR (400 MHz, CD_3OD): δ 1.08 (m, 3H), 1.21 (m,

45

3H), 2.31 (br s, 2H), 3.04 (br s, 2H), 3.24 (m, 4H), 3.37 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.37 (s, 2H), 4.43 (s, 1H), 7.09 (m, 1H), 7.21 (m, 3H), 7.32 (d, J = 8.2 Hz, 2H), 7.55 (m, 3 H), 7.68 (m, 2H). Anal. calcd for C₂₉H₃₆N₄O₃S x 1.4 C₂HF₃O₂ x 1.0 H₂O: C, 54.69; H, 5.69; N, 8.02. Found: C, 54.74; H, 5.63; N, 8.16. M.S. (calcd): 521.26 (MH⁺), M.S. (found): 521.25 (MH⁺). HPLC: k': 6.67; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >99% (215nm) >99% (254nm) >99% (280nm), Retention time: 9.0 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: [α]_D¹⁷ = -12.9° (c = 1.13, MeOH).

COMPOUND 7: S-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(2-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate



15


Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 2-furaldehyde (58 μL, 0.70 mmol) afforded 172 mg of **COMPOUND 7**. ¹H NMR (400 MHz, CD₃OD): δ 1.08 (m, 3H), 1.22 (m, 3H), 2.36 (br s, 2H), 3.02 (br s, 2H), 3.31 (m, 6H), 3.51 (m, 2H), 3.72 (s, 3H), 4.42 (s, 2H), 4.44 (s, 1H), 6.52 (dd, J=1.9, 3.1 Hz, 1H), 6.71 (d, J = 3.3 Hz, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 7.66 (m, 1H), 7.69 (s, 1H). Anal. calcd for C₂₉H₃₆N₄O₄ x 1.5 C₂HF₃O₂ x 0.6 H₂O: C, 55.99; H, 5.68; N, 8.16. Found: C, 56.02; H, 5.74; N, 8.22. M.S. (calcd): 505.28 (MH⁺), M.S. (found): 505.26 (MH⁺). HPLC: k': 5.92; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >95% (215nm), >95%

25

46

(254nm), >96% (280nm), Rt: 8.3 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_D = +14.4^\circ$ (c = 1.06, MeOH).


COMPOUND 8: *R*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}{4-(2-furylmethyl)piperazin-1-yl}methyl}phenylcarbamate



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 2-furaldehyde (58 μ L, 0.70 mmol) afforded 50 mg of **COMPOUND 8**. ^1H NMR (400 MHz, CD_3OD): δ 1.09 (m, 3H), 1.22 (m, 3H), 2.32 (br s, 2H), 3.06 (br s, 2H), 3.24 (m, 4H), 3.40 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.42 (s, 2H), 4.44 (s, 1H), 6.53 (dd, J=1.8, 3.1 Hz, 1H), 6.71 (d, J = 3.3 Hz, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 7.67 (m, 1H), 7.70 (s, 1H). Anal. calcd for $\text{C}_{29}\text{H}_{36}\text{N}_4\text{O}_4 \times 1.6 \text{ C}_2\text{HF}_3\text{O}_2 \times 0.3 \text{ H}_2\text{O}$: C, 55.85; H, 5.56; N, 8.09. Found: C, 55.76; H, 5.50; N, 8.25. M.S. (calcd): 505.28 (MH^+), M.S. (found): 505.27 (MH^+). HPLC: k' : 6.00; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 7.2 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_D = -13.8^\circ$ (c = 0.97, MeOH).


COMPOUND 9: *S*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}{4-(3-furylmethyl)piperazin-1-yl}methyl}phenylcarbamate

47



- Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 3-furaldehyde (58 μ L, 0.70 mmol) afforded 167 mg of
- 5 **COMPOUND 9**. ^1H NMR (400 MHz, CD_3OD): δ 1.09 (m, 3H), 1.22 (m, 3H), 2.32 (br s, 2H), 3.06 (br s, 2H), 3.24 (m, 4H), 3.40 (m, 2H), 3.51 (m, 2H), 3.72 (s, 3H), 4.42 (s, 2H), 4.44 (s, 1H), 6.53 (dd, $J=1.8, 3.1$ Hz, 1H), 6.71 (d, $J = 3.3$ Hz, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, $J = 8.2$ Hz, 2H), 7.55 (d, $J = 8.2$ Hz, 2H), 7.67 (m, 1H), 7.70 (s, 1H). Anal. calcd for $\text{C}_{29}\text{H}_{36}\text{N}_4\text{O}_4 \times 2.0 \text{ C}_2\text{HF}_3\text{O}_2 \times 0.5 \text{ H}_2\text{O}$: C, 53.44; H, 5.30; N, 7.55. Found: C, 53.42; H, 5.28; N, 7.68. M.S. (calcd): 505.28 (MH^+), M.S. (found): 505.27 (MH^+). HPLC: k' : 5.99; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >97% (215nm) >97% (254nm) >97% (280nm), Rt: 13.8 min; Chiral HPLC Conditions:
- 15 Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{17}_{\text{D}} = +13.9^\circ$ ($c = 0.94$, MeOH).


COMPOUND 10: *R*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(3-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate



- 20 Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 3-furaldehyde (58 μ L, 0.70 mmol) afforded 119 mg of
- COMPOUND 10**. ^1H NMR (400 MHz, CD_3OD): δ 1.09 (m, 3H), 1.22 (m, 3H), 2.32


(br s, 2H), 3.05 (br s, 2H), 3.21 (m, 4H), 3.47 (m, 4H), 3.72 (s, 3H), 4.24 (s, 2H), 4.43 (s, 1H), 6.58 (m, 1H), 7.09 (m, 1H), 7.20 (m, 2H), 7.32 (d, $J = 8.2$ Hz, 2H), 7.55 (d, $J = 8.2$ Hz, 2H), 7.63 (m, 1H), 7.70 (s, 1H), 7.76 (s, 1H). Anal. Calcd for $C_{29}H_{36}N_4O_4 \times 1.5 C_2HF_3O_2 \times 0.2 H_2O$: C, 56.58; H, 5.62; N, 8.25. Found: C, 56.50; H, 5.56; N, 8.31. M.S. (calcd): 505.28 (MH^+), M.S. (found): 505.27 (MH^+). HPLC: k' : 6.02; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 8.7 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]_D^{17} = -14.9^\circ$ ($c = 1.10$, MeOH).

COMPOUND 11: *R*-Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1*H*-imidazol-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 2-imidazolecarboxaldehyde (68mg, 0.70 mmol) afforded 141 mg of **COMPOUND 11**. 1H NMR (400 MHz, CD_3OD): δ 1.09 (m, 3H), 1.23 (m, 3H), 2.82 (br s, 4H), 3.02 (br s, 4H), 3.24 (m, 2H), 3.52 (m, 2H), 3.73 (s, 3H), 3.98 (s, 2H), 5.03 (s, 1H), 7.27 (m, 3H), 7.42 (d, $J = 8.0$ Hz, 2H), 7.49 (m, 2H), 7.67 (d, $J = 8.0$ Hz, 2H), 7.84 (s, 1H). Anal. calcd for $C_{28}H_{36}N_6O_3 \times 2.1 C_2HF_3O_2 \times 1.5 H_2O$: C, 50.16; H, 5.37; N, 10.90. Found: C, 50.06; H, 5.27; N, 11.02. M.S. (calcd): 505.29 (MH^+), M.S. (found): 505.28 (MH^+). HPLC: k' : 2.55; Purity: >98% (215nm), >97% (254nm), >97% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 12.5 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]_D^{16} = -3.33^\circ$ ($c = 1.08$, MeOH).

COMPOUND 12: *S*-Methyl3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate



5

Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 2-pyridine carboxaldehyde (76 mg, 0.70 mmol) afforded 213 mg of **COMPOUND 12**. ^1H NMR (400 MHz, CD_3OD): δ 1.08 (m, 3H), 1.22 (m, 3H), 2.74 (br s, 4H), 3.24 (m, 2H), 3.41 (m, 4H), 3.51 (m, 2H), 3.72 (s, 3H), 4.48 (s, 2H),

10

4.48 (s, 1H), 7.11 (m, 1H), 7.21 (m, 2H), 7.33 (d, $J = 7.7$ Hz, 2 H), 7.43 (m, 1H), 7.48 (m, 1H), 7.57 (d, $J = 7.7$ Hz, 2 H), 7.73 (s, 1H), 7.89 (s, 1H), 8.66 (m, 1H). Anal.


calcd for $\text{C}_{30}\text{H}_{37}\text{N}_5\text{O}_3 \cdot 1.5 \text{ C}_2\text{HF}_3\text{O}_2 \cdot 1.2 \text{ H}_2\text{O}$: C, 55.96; H, 5.82; N, 10.01. Found: C, 55.93; H, 5.73; N, 10.01. M.S. (calcd): 516.30 (MH^+), M.S. (found): 516.29 (MH^+). HPLC: k' : 0.88; Purity: >99% (215nm), >99% (254nm), >99% (280nm).

15

HPLC Conditions: Zorbax C-18, gradient 30-80% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 12.9 min; Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{16}_{\text{D}} = +16.5^\circ$ ($c = 1.24$, MeOH).


20

COMPOUND 13: *R*-Methyl3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 2-pyridine carboxaldehyde (76 mg, 0.70 mmol) afforded 187 mg of **COMPOUND 13**. ¹H NMR (400 MHz, CD₃OD): δ 1.08 (m, 3H), 1.21 (m, 3H), 2.75 (br s, 4H), 3.24 (m, 2H), 3.41 (m, 4H), 3.51 (m, 2H), 3.72 (s, 3H), 4.48 (s, 2H), 4.48 (s, 1H), 7.11 (m, 1H), 7.20 (m, 2H), 7.33 (d, J = 8.0 Hz, 2 H), 7.43 (m, 1H), 7.48 (m, 1H), 7.57 (d, J = 8.0 Hz, 2 H), 7.73 (s, 1H), 7.89 (s, 1H), 8.66 (m, 1H). Anal. calcd for C₃₀H₃₇N₅O₃ x 1.7 C₂HF₃O₂ x 0.8 H₂O: C, 55.42; H, 5.61; N, 9.67. Found: C, 55.40; H, 5.62; N, 9.83. M.S. (calcd): 516.30 (MH⁺), M.S. (found): 516.28 (MH⁺). HPLC: k': 3.02; Purity: >97% (215nm), >98% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 11.3 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: [α]_D¹⁶ = -15.4° (c = 1.01, MeOH).


COMPOUND 14: *S*-Methyl3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-4-ylmethyl) piperazin-1-yl] methyl}phenylcarbamate



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4b** (200 mg, 0.47 mmol) and 4-pyridine carboxaldehyde (76 mg, 0.70 mmol) afforded 217 mg of **COMPOUND 14**. ¹H NMR (Free Amine, 400 MHz, CDCl₃): δ 1.09 (br s, 3H), 1.21 br s, 3H), 2.43 (m, 8H), 3.24 (br s, 2H), 3.50 (s, 2H), 3.51 (br s, 2H), 3.76 (s, 3H), 4.22 (s, 1H), 6.63 (s, 1H), 7.10 (m, 1H), 7.22 (m, 4H), 7.28 (d, J = 8.2 Hz, 2 H), 7.42 (m, 1H), 7.42 (d, J = 8.2 Hz, 2 H), 8.52 (s, 2H). Anal. calcd for C₃₀H₃₇N₅O₃ x 1.9 C₂HF₃O₂ x 1.8 H₂O: C, 53.09; H, 5.60; N, 9.16. Found: C, 53.04; H, 5.60; N, 9.18. M.S. (calcd): 516.30 (MH⁺), M.S. (found): 516.28 (MH⁺). HPLC: k': 2.69; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B:

0.1% TFA in CH₃CN; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 12.9 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: $[\alpha]^{16}_D = +10.3^\circ$ (c = 1.25, MeOH).

5 **COMPOUND 15:** *R*-Methyl3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-4-ylmethyl) piperazin-1-yl] methyl}phenylcarbamate




Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (200 mg, 0.47 mmol) and 4-pyridine carboxaldehyde (76 mg, 0.70 mmol) afforded 247 mg

- 10 of **COMPOUND 15**. ¹H NMR (Free Amine, 400 MHz, CDCl₃): δ 1.09 (br s, 3H), 1.21 (br s, 3H), 2.45 (m, 8H), 3.24 (br s, 2H), 3.50 (s, 2H), 3.51 (br s, 2H), 3.76 (s, 3H), 4.22 (s, 1H), 6.64 (s, 1H), 7.10 (m, 1H), 7.22 (m, 4H), 7.28 (d, J = 8.2 Hz, 2 H), 7.42 (m, 1H), 7.42 (d, J = 8.2 Hz, 2 H), 8.52 (d, J = 5.7 Hz, 2 H). Anal. calcd for C₃₀H₃₇N₅O₃ x 2.6 C₂HF₃O₂ x 1.0 H₂O: C, 50.93; H, 5.05; N, 8.44 Found: C, 50.89; H, 5.07; N, 8.50. M.S. (calcd): 516.30 (MH⁺), M.S. (found): 516.28 (MH⁺). HPLC: k': 2.69; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 16.3 min; Conditions: Chiralpak AD, 30 % IPA/70%
20 hexane. Rotation: $[\alpha]^{16}_D = -8.1^\circ$ (c = 1.10, MeOH).


COMPOUND 16: *R*-Methyl3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-2-ylmethyl)-piperazin-1-yl]methyl}phenylcarbamate

52



Using the same method as for **COMPOUND 1** and using **INTERMEDIATE 4a** (140 mg, 0.33 mmol) and 2-thiazole carboxaldehyde (45 mg, 0.39 mmol) afforded 85 mg of **COMPOUND 16**. ¹H NMR (Free Amine, 400 MHz, CDCl₃): δ 1.09 (br s, 3H), 1.21 (br s, 3H), 2.44 (br s, 4H), 2.61 (br s, 4H), 3.23 (br s, 2H), 3.51 (br s, 2H), 3.76 (s, 3H), 3.88 (s, 2H), 4.23 (s, 1H), 6.61 (s, 1H), 7.11 (m, 1H), 7.23 (m, 3H), 7.28 (d, J = 8.2 Hz, 2H), 7.41 (m, 1H), 7.43 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 3.3 Hz, 1H). M.S. (calcd): 522.3 (MH⁺), M.S. (found): 522.2 (MH⁺) HPLC: k': 4.09; Purity: >99% (215nm), >99% (254nm), >99% (280nm). HPLC Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H₂O, B: 0.1% TFA in CH₃CN; Chiral Purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time: 9.5 min; Chiral HPLC Conditions: Chiralpak AD, 30 % IPA/70% hexane. Rotation: [α]_D¹⁶ = -12.08° (c = 1.01, MeOH).


COMPOUND 17: [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl-carbamic acid, methyl ester



INTERMEDIATE 3 was methylated with sodium hydride/methyl iodide and the Boc group cleaved with TFA. The secondary amine was reacted with benzaldehyde and

sodium triacetoxyborohydride to give racemic **COMPOUND 17**. This material was purified by chiral HPLC on Chiralpak AD 25 % EtOH/75% Heptane to yield enantiomerically pure **COMPOUND 17**. ^1H NMR (400 MHz, CD_3OD): δ 1.09 (m, 3H), 1.22 (m, 3H), 2.31 (m, 2H), 3.05 (m, 2H), 3.25 (m, 4H), 3.25 (s, 3H), 3.40 (m, 2H), 3.51 (m, 2H), 3.83 (s, 3H), 4.34 (s, 2H), 4.50 (s, 1H), 7.15 (m, 1H), 7.32 (m, 4H), 7.43 (s, 1H), 7.49 (s, 5H), 7.55 (d, $J = 8.2$ Hz, 2 H). M.S. (calc'd): 529.3 (MH^+), M.S. (found): 529.2 (MH^+). HPLC: k' : 2.42; Purity: >99% (215nm), >99% (254nm), >99% (280nm). Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm) >98% (254nm) >99% (280nm), Retention time: 7.01 min; Conditions: Chiralpak AD, 30 % IPA/70% hexane. $[\alpha]_D^{16} = -15.69^\circ$ ($c = 1.06$, MeOH).

COMPOUND 18: [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester




Methyl chloroformate (0.042mL, 0.54 mmol) and zinc dust (35mg, 0.54 mmol) were stirred together in 3 mL of dry toluene at room temperature under nitrogen for 10 minutes. A 8 mL toluene solution of **INTERMEDIATE 14** (247mg, 0.54mmol) was then added dropwise and the reaction mixture was stirred at room temperature for one hour. The solution was then diluted with dichloromethane and filtered. The organic phase was washed with saturated NaHCO_3 solution, brine and dried over anhydrous Na_2SO_4 . The product was purified by silica gel flash chromatography eluting 30% hexanes in acetone rising to 27% hexanes, 3% methanol in acetone to afford **COMPOUND 18**. ^1H NMR (400MHz, CDCl_3) δ 1.09 (br s, 3H), 1.21 (br s, 3H), 2.31-2.54 (m, 8H), 3.23 (br s, 2H), 3.47-3.56 (m, 4H), 3.76 (s, 3H), 4.21 (s, 1H), 6.68

(br s, 1H), 7.08 (dt, $J = 7.21\text{Hz}$ 1.61Hz, 1H), 7.18-7.25 (m, 3H), 7.27 (d, $J = 7.86\text{Hz}$, 2H), 7.41 (d, $J = 8.02\text{Hz}$, 2H), 7.64 (dt, $J = 7.69\text{Hz}$ 1.92Hz, 1H), 8.49 (dd, $J = 4.97\text{Hz}$, 1.60Hz, 1H), 8.52 (d, $J = 1.76\text{Hz}$, 1H). Found: C, 56.47; H, 6.76; N, 10.71.

$\text{C}_{30}\text{H}_{37}\text{N}_5\text{O}_3 \times 1.0 \text{ H}_2\text{O} \times 2.9 \text{ HCl} \times 0.2 \text{ C}_4\text{H}_{10}\text{O}$ has C, 56.55; H, 6.76; N, 10.70 %.

- 5 M.S. (calc'd): 516.3 (MH^+), M.S. (found): 516.2 (MH^+). HPLC: k' : 4.27; Purity: >99% (215nm), >99% (254nm), >99% (280nm). Conditions: Zorbax C-18, gradient 10-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm) >98% (254nm) >99% (280nm), Retention time: 6.66 min; Chiral HPLC Conditions: Chiralpak AD, 50 % ethanol/50% hexane.
- 10 Rotation: $[\alpha]_{\text{D}} = +7.64^\circ$ ($c = 0.497$, MeOH).

COMPOUND 19: [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester



15

Methyl chloroformate (0.031mL, 0.40 mmol) and zinc dust (26mg, 0.40 mmol) were stirred together in 2 mL of dry toluene at room temperature under nitrogen for 10 minutes. A 5 mL toluene solution of **INTERMEDIATE 15** (185mg, 0.40mmol) was then added dropwise and the reaction mixture was stirred at room temperature for one hour. The solution was then diluted with dichloromethane and filtered. The organic phase was washed with saturated NaHCO_3 solution, brine and dried over anhydrous Na_2SO_4 . The product was purified by silica gel flash chromatography eluting 30% hexanes in acetone rising to 27% hexanes, 3% methanol in acetone to afford

- 25 **COMPOUND 19.** ^1H NMR (400MHz, CD_3OD) δ 1.06 (t, $J = 6.49\text{Hz}$, 3H), 1.19 (t, $J = 6.93\text{Hz}$, 3H), 2.90-3.10 (m, 2H), 3.17-3.25 (m, 2H), 3.33-3.42 (m, 4H), 3.45-3.52


(m, 2H), 3.70 (s, 3H), 4.59 (s, 2H), 7.16-7.23 (m, 1H), 7.26 (d, J = 4.00Hz, 2H), 7.36 (d, J = 7.81Hz, 2H), 7.65 (d, J = 7.32Hz, 2H), 7.73-7.8 (m, 2H), 7.88-7.93 (m, 1H).

Found: C, 56.81; H, 6.53; N, 11.56. $C_{28}H_{35}N_5O_3S \times 0.90H_2O \cdot 1.5HCl$ has C, 56.75; H, 6.51; N, 11.82%. M.S. (calc'd): 522.3 (MH^+), M.S. (found): 522.2 (MH^+). HPLC: k':

5 3.99; Purity: >99% (215nm), >99% (254nm), >99% (280nm). Conditions: Zorbax C-18, gradient 20-50% B in 25 min, flow: 1mL/min, 25°C, A: 0.1% TFA in H_2O , B: 0.1% TFA in CH_3CN ; Chiral Purity: >99% (215nm) >99% (254nm) >99% (280nm), Retention time: 20.31 min; Chiral HPLC Conditions: Chiralpak AD, 30 % ethanol/70% hexane. Rotation: $[\alpha]_D = +9.13^\circ$ (c = 1.06, MeOH).

10

COMPOUND 20: Methyl 3-[(R)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl]phenylcarbamate



15

To a solution of optically pure **INTERMEDIATE 4a** (0.150 g, 0.35 mmol) in 4 ml of DMF was added K_2CO_3 (0.122g, 0.88 mmol) and 4-(chloromethyl)-1,3-thiazole (0.066 g, 0.39 mmol) and the mixture was heated at 60 °C overnight. The solvent was evaporated and the crude material was dissolved in dichloromethane, washed with


20 water then brine. The organic extract was dried over Na_2SO_4 , filtered and concentrated to give crude product that was purified by reverse phase HPLC (gradient 5-50 % CH_3CN in H_2O containin 0.1 % TFA) to give **COMPOUND 20** (0.030 g,

11.3% yield) as the TFA salt. This material was lyophilized from CH_3CN/H_2O to produce white powder. 1H NMR (400MHz, CD_3OD) δ 1.09 (t, J = 6.6 Hz, 3H), 1.22 (t, J = 6.8 Hz, 3H), 2.36 (br s., 2H), 3.04 (br s., 2H), 3.19-3.35 (m, 4H), 3.42 (br s., 2H), 3.51 (q, J = 6.6 Hz, 2H), 3.72 (s, 3H), 4.45 (s, 1H), 4.52 (s, 2H), 7.10 (dt, J = 1.5, 7.0 Hz, 1H), 7.16-7.24 (m, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.71, (s, 1H), 7.84 (s, 1H), 9.1 (s, 1H). Purity (HPLC): >89% (215nm), >99%

25

(254nm), >99% (280nm); Conditions: Zorbax C-18, gradient: 10-95% B in 25 min, flow: 1mL/min, 40° C, A - 0.1% Formic Acid in H₂O, B - 0.1% Formic Acid in MeCN; Chiral purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time 6.67 min; Conditions: Chiralpak AD 50%IPA/50%hexane. Rotation $[\alpha]_D^{18} = -14.7^\circ$ (c = 0.88, MeOH)

COMPOUND 21: Methyl 3-{(S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate




To a solution of optically pure **INTERMEDIATE 4b** (0.225 g, 0.53 mmol) in 4 ml of DMF was added K₂CO₃ (0.183g, 1.33 mmol) and 4-(chloromethyl)-1,3-thiazole (0.099 g, 0.58 mmol) and the mixture was heated at 60 °C overnight. The solvent was evaporated and the crude material was dissolved in dichloromethane, washed with water then brine. The organic extract was dried over Na₂SO₄, filtered and concentrated to give crude product that was purified by reverse phase HPLC (gradient 5-50 % CH₃CN in H₂O containin 0.1 % TFA) to give **COMPOUND 21** (0.166 g, 41.7% yield) as the TFA salt. This material was lyophilized from CH₃CN/H₂O to produce white powder. ¹H NMR (400MHz, CD₃OD) δ 0.97 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.8 Hz, 3H), 2.25 (br s., 2H), 2.91 (br s., 2H), 3.07-3.21 (m, 4H), 3.31 (br s., 2H), 3.41 (q, J = 6.8 Hz, 2H), 3.61 (s, 3H), 4.34 (s, 1H), 4.41 (s, 2H), 6.99 (dt, J = 1.6, 7.0 Hz, 1H), 7.05-7.13 (m, 2H), 7.22 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.60 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 8.99 (d, J = 2.0 Hz, 1H), 9.13 (s, 1H).

Anal.calcd for C₂₈H₃₅N₅O₃S x 1.8TFA x 1.1H₂O: C, 50.83; H, 5.26; N, 9.38. Found: C, 50.82; H, 5.23; N, 9.33. MS (calcd): 552.2 (MH⁺), MS (found): 552.2 (MH⁺). Purity (HPLC): >99% (215nm), >99% (254nm), >99% (280nm); Conditions: Zorbax C-18, gradient: 10-95% B in 25 min, flow: 1mL/min, 40° C, A - 0.1% Formic Acid in


H₂O, B - 0.1% Formic Acid in MeCN; Chiral purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time 6.66 min; Conditions: Chiralpak AD 50%IPA/50%hexane. Rotation $[\alpha]^{18}_D = +14.5^\circ$ (c = 1.07, MeOH)

5 **COMPOUND 22: Methyl 3-{(R)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-5-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate**



To a solution of **INTERMEDIATE 4a** (0.163 g, 0.38 mmol) in 1,2 dichloroethane (6 ml) was added thiazole-5-carboxaldehyde (0.087 g, 0.77mmol) and NaHB(OAc)₃ (0.163 g, 0.77 mmol). The reaction was stirred overnight at room temperature and was quenched with saturated aqueous NaHCO₃. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 15mL). The combined organic layers were washed with H₂O, brine, then dried over Na₂SO₄, filtered, concentrated and purified by reverse phase HPLC (gradient 5-50 % CH₃CN in H₂O containing 0.1 % TFA) to give **COMPOUND 22** (0.205 g, 71.2 % yield) as the TFA salt. This material was lyophilized from CH₃CN/H₂O to produce a pale yellow solid. ¹H NMR (400MHz, CD₃OD) δ 1.09 (t, J = 6.8 Hz, 3H), 1.22 (t, J = 6.8 Hz, 3H), 2.77 (br s., 4H), 3.18-3.40 (m, 6H), 3.51 (q, J = 7.0 Hz, 2H), 3.72 (s, 3H), 4.56 (s, 1H), 4.63 (s, 2H), 7.12 (dt, J = 1.9, 8.4 Hz, 1H), 7.19 (dt, J = 1.95, 8.4 Hz, 1H), 7.21-7.26 (m, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.74 (s, 1H), 8.05 (s, 1H), 9.17 (s, 1H). Anal.calcd for C₂₈H₃₅N₅O₃S x 2.6TFA x 0.3H₂O: C, 48.42; H, 4.68; N, 8.50. Found: C, 48.49; H, 4.83; N, 8.30. MS (calcd): 552.2 (MH⁺), MS (found): 552.2 (MH⁺). Purity (HPLC): >99% (215nm), >99% (254nm), >99% (280nm); Conditions: Zorbax C-18, gradient: 10-95% B in 25 min, flow: 1mL/min, 40° C, A - 0.1% Formic Acid in H₂O, B - 0.1% Formic Acid in MeCN; Chiral purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time 9.92 min; Conditions: Chiralpak AD 50%IPA/50%hexane. Rotation $[\alpha]^{18}_D = -12.4^\circ$ (c = 1.01, MeOH).

COMPOUND 23: Methyl 3-[(S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-5-ylmethyl)piperazin-1-yl]methyl]phenylcarbamate



5

To a solution of **INTERMEDIATE 4b** (0.223 g, 0.53 mmol) in 1,2 dichloroethane (8 ml) was added thiazole-5-carboxaldehyde (0.119 g, 1.05 mmol) and NaHB(OAc)₃ (0.223, 1.05 mmol). The reaction was stirred overnight and quenched with saturated aqueous NaHCO₃. The layers were separated and the aqueous phase was extracted with dichloromethane (2 x 15mL). The combined organic extracts were washed with H₂O, brine, dried over Na₂SO₄, filtered, concentrated and purified by reverse phase HPLC (gradient 5-50 % CH₃CN in H₂O containing 0.1 % TFA) to give

10

COMPOUND 23 (0.214 g, 54.2% yield) as the TFA salt. This material was

15

lyophilized from CH₃CN/H₂O to produce a yellow solid. ¹H NMR (400MHz, CD₃OD) δ 1.09 (t, J = 6.3 Hz, 3H), 1.22 (t, J = 6.6 Hz, 3H), 2.52 (br s., 2H), 2.97 (br s., 2H), 3.18-3.40 (m, 6H), 3.51 (q, J = 6.8 Hz, 2H), 3.72 (s, 3H), 4.56 (s, 1H), 4.64 (s, 2H), 7.11 (dt, J = 1.56, 7.4 Hz, 1H), 7.17-7.21 (m, 1H), 7.21-7.26 (m, 1H), 7.35 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.4 Hz), 7.74 (s, 1H), 8.05 (s, 1H), 9.17 (s, 1H). Purity


20

(HPLC): >98% (215nm), >99% (254nm), >99% (280nm); Conditions: Zorbax C-18, gradient: 10-95% B in 25 min, flow: 1mL/min, 40° C, A - 0.1% Formic Acid in H₂O, B - 0.1% Formic Acid in MeCN; Chiral purity: >99% (215nm), >99% (254nm), >99% (280nm), Retention time 13.26 min; Conditions: Chiralpak AD 50%IPA/50%hexane. Rotation [α]_D¹⁸ = +12.7° (c = 0.97, MeOH).

25

What is claimed is :

1. A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



5

wherein

- R^1 is selected from $-H$, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups selected from $-R$, $-NO_2$, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl;

- R^2 is selected from $-H$, C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl; and

- R^3 is selected from C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl.

25

2. A compound according to claim 1, wherein

R^1 is $-\text{CH}_2-\text{R}^4$, wherein R^4 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-\text{NO}_2$, $-\text{CF}_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

R^2 is selected from $-\text{H}$ and C_{1-3} alkyl; and

R^3 is selected from C_{1-6} alkyl, and C_{3-6} cycloalkyl.

3. A compound according to claim 2,

wherein R^4 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl and thiazolyl;

R^2 is selected from $-\text{H}$ and methyl; and

R^3 is selected from methyl, ethyl, propyl and isopropyl.

4. A compound according to claim 1, wherein

R^1 is $-\text{H}$;

R^2 is selected from $-\text{H}$ and C_{1-3} alkyl; and

R^3 is selected from C_{1-6} alkyl, and C_{3-6} cycloalkyl.

5. A compound according to claim 1, wherein the compound is selected from:

Methyl 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-yl)methyl]phenylcarbamate;

Methyl-3-{ {4-[(diethylamino)carbonyl]phenyl} [4-(thien-2-ylmethyl)piperazin-1-yl]methyl} phenylcarbamate;

Methyl 3-{ {4-[(diethylamino)carbonyl]phenyl} [4-(thien-3-ylmethyl)piperazin-1-yl]methyl} phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(2-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

5 Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(3-furylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1H-imidazol-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

10 Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(pyridin-4-yl-methyl)piperazin-1-yl] methyl}phenylcarbamate;

15

Methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-2-ylmethyl)-piperazin-1-yl]methyl}phenylcarbamate;

20 [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-carbamic acid methyl ester;

[3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester;

25 [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]- carbamic acid, methyl ester;

Methyl 3-((R)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

30

Methyl 3-((S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate;

Methyl 3- $\{ (R) \text{-} \{ 4 \text{-} [(\text{diethylamino}) \text{carbonyl}] \text{phenyl} \} [4 \text{-} (1,3 \text{-thiazol-5-ylmethyl}) \text{piperazin-1-yl}] \text{methyl} \} \text{phenyl} \text{carbamate} ;$

- 5 Methyl 3- $\{ (S) \text{-} \{ 4 \text{-} [(\text{diethylamino}) \text{carbonyl}] \text{phenyl} \} [4 \text{-} (1,3 \text{-thiazol-5-ylmethyl}) \text{piperazin-1-yl}] \text{methyl} \} \text{phenyl} \text{carbamate} ;$

$[3 \text{-} [[4 \text{-} [(\text{diethylamino}) \text{carbonyl}] \text{phenyl}] \text{-} 1 \text{-piperazinylmethyl}] \text{phenyl}] \text{- carbamic acid, methyl ester} ;$

- 10 enantiomers thereof; and pharmaceutically acceptable salts thereof.

6. A compound according to any one of claims 1-5 for use as a medicament.

7. The use of a compound according to any one of claims 1-5 in the manufacture
15 of a medicament for the therapy of pain, anxiety or functional gastrointestinal disorders.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.

20


9. A method for the therapy of pain in a warm-blooded animal, comprising: administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

- 25 10. A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising: administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.


11. A method for the therapy of anxiety in a warm-blooded animal, comprising:
30 administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

63


12. A process for preparing a compound of formula II, comprising:

II

5 a) reacting a compound of formula III:


III

with a compound of formula IV

IV

10 in the presence of benzotriazole; and

b) reacting a product formed in step a) with a compound of formula V to form the compound of formula II,

V

15 wherein

64


R^8 is selected from C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

M is selected from Li, Na, K, $-ZnX^1$, and $-MgX^1$, wherein X^1 is a halogen; and

R^9 is selected from hydrogen, $-R$, $-NO_2$, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, and $-NRC(=O)-OR$, wherein R is,

independently, a hydrogen or C_{1-6} hydrocarbyl.


13. A process for preparing a compound of formula VII:



VII,

15 comprising:

reacting a compound of formula VIII



VIII

with a C_{1-6} alkylcarbamate to form the compound of formula VII,

wherein


R^8 is selected from C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C_{1-6} alkyl;

X is selected from halogen, triflate, and sulfonamide; and

R^{11} is a C_{1-6} alkyl.


10

14. A process for preparing a compound of formula X,



comprising:

15 reacting a compound of formula IX,



with R^4 -CHO to form the compound of formula X,


wherein

R^4 is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, wherein said phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, -NO₂, -CF₃, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

R^2 is selected from -H, C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C_{1-6} alkyl; and

R^3 is selected from -H, C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C_{1-6} alkyl.

15. A compound of formula XI, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



XI

wherein

R^1 is selected from -H, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl, wherein said C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, and C_{2-6} heteroaryl- C_{1-4} alkyl are optionally substituted with one or more groups

67

selected from -R, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, and -NRC(=O)-OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001707

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 295/155, C07D 333/20, C07D 307/52, C07D 213/36, C07D 277/28,
A61K 31/495, A61K 31/496, A61P 25/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9315062 A1 (THE WELLCOME FOUNDATION LIMITED), 5 August 1993 (05.08.1993) --	1-14
P,X	WO 02094794 A1 (ASTRAZENECA AB), 28 November 2002 (28.11.2002), examples 9 and 10 -- -----	15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 February 2004

Date of mailing of the international search report

24-02-2004

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Solveig Gustavsson/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001707

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **9-11**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2003/001707

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

Claims 9-11 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

24/12/2003

International application No.

PCT/SE 2003/001707

WO	9315062	A1	05/08/1993	AT	192197	T	15/05/2000
				AT	237597	T	15/05/2003
				AU	675928	B	27/02/1997
				AU	3457393	A	01/09/1993
				CA	2129046	A	05/08/1993
				DE	69230974	D,T	19/10/2000
				DE	69332882	D	00/00/0000
				DK	649414	T	11/08/2003
				EP	0649414	A,B	26/04/1995
				SE	0649414	T3	
				EP	0650536	A,B	03/05/1995
				GB	9202238	D	00/00/0000
				IL	104582	A	30/10/1998
				JP	3109832	B	20/11/2000
				JP	3392415	B	31/03/2003
				JP	7501583	T	16/02/1995
				JP	7503247	T	06/04/1995
				NZ	246916	A	27/08/1996
				PT	649414	T	30/09/2003
				US	5492737	A	20/02/1996
				US	5574159	A	12/11/1996
				US	5658908	A	19/08/1997
				US	5681830	A	28/10/1997
				US	5854249	A	29/12/1998
				US	2002052007	A	02/05/2002
				ZA	9300717	A	02/08/1994
<hr/>							
WO	02094794	A1	28/11/2002	AU	8040901	A	13/03/2002
				SE	0101772	D	00/00/0000
				SE	0103820	D	00/00/0000

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041802 A1

(51) International Patent Classification⁷: **C07D 295/155**,
333/20, 307/52, 213/36, 277/28, A61K 31/495, 31/496,
A61P 25/04

7171 Frederick-Banting, St. Laurent, Montreal, Québec
H4S 1Z9 (CA).

(21) International Application Number:
PCT/SE2003/001707

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:
5 November 2003 (05.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203303-3 7 November 2002 (07.11.2002) SE

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BROWN, William**
[CA/CA]; AstraZeneca R & D Montreal, 7171 Freder-
ick-Banting, St. Laurent, Montreal, Québec H4S 1Z9
(CA). **GRIFFIN, Andrew** [GB/CA]; AstraZeneca R &
D Montreal, 7171 Frederick-Banting, St. Laurent, Mon-
treal, Québec H4S 1Z9 (CA). **JONES, Paul** [CA/CA];
AstraZeneca R & D Montreal, 7171 Frederick-Banting,
St. Laurent, Montreal, Québec H4S 1Z9 (CA). **PAGE,
Daniel** [CA/CA]; AstraZeneca R & D Montreal, 7171
Frederick-Banting, St. Laurent, Montreal, Québec H4S
1Z9 (CA). **PLOBECK, Niklas** [SE/SE]; AstraZeneca R
& D Södertälje, S-151 85 Södertälje (SE). **WALPOLE,
Christopher** [GB/CA]; AstraZeneca R & D Montreal,

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,

[Continued on next page]

(54) Title: 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS



(57) Abstract: Compounds of general formula (I) wherein R₁, R₂ and R₃ are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

(I)

WO 2004/041802 A1



KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— *with international search report*

(48) Date of publication of this corrected version:

10 March 2005

(15) Information about Correction:

see PCT Gazette No. 10/2005 of 10 March 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.